Takeda announces 4-year survival data from ADCETRIS® pivotal trial at ASH annual meeting
Takeda UK announced 4-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase II clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic ALCL, a type of T-cell lymphoma.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Other conferences & symposia Oncology Patient care ALCL antibody-drug conjugate brentuximab vedotin Hodgkin lymphoma Latest News Source Type: news
More News: Cancer & Oncology | Clinical Trials | Conferences | Drugs & Pharmacology | Lymphoma | T-cell Lymphoma